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ABSTRACT
Esophageal carcinoma (EC) is a global health problem, with disappointing 
5-year survival rates of only 15–25%. Near-infrared targeted photodynamic 
therapy (NIR-tPDT) is a novel strategy in which cancer-targeted phototoxicity is 
able to selectively treat malignant cells. In this in vitro report we demonstrate the 
applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using 
the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, 
targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2). 
Furthermore, we demonstrate that NIR-tPDT can be made more effective by tyrosine 
kinase inhibitor (TKI) induced growth receptor upregulation. Together, these results 
unveil a novel strategy for non-invasive EAC treatment, and by pretreatment-induced 
receptor upregulation its future clinical application may be optimized.
INTRODUCTION
Esophageal cancer (EC) is a global health problem. 
EC is the sixth leading cause of cancer related mortality 
and the eighth most commonly diagnosed cancer in the 
world [1]. EC can be roughly divided into two cancer types: 
squamous cell carcinoma (SCC), of which the incidence 
rates have been decreasing, and esophageal adenocarcinoma 
(EAC). Over the past few decades risk factors such as 
obesity and gastroesophageal reflux disease (GERD), which 
are both progressive problems of the Western countries, 
have caused the incidence rates of EAC to increase [2]. In 
addition, the current prognosis of EC remains poor, resulting 
in 5-year survival rates of only 15–25% [3]. 
Detection and treatment of EAC in an early stage of 
the disease is essential to improve its outcome [4]. Surgical 
resection is an invasive treatment option and carries a high 
risk for morbidity and mortality [5,6]. When EAC is in its 
limited disease-stage, superficial and still restricted to the 
mucosa, non-invasive endoscopic resection is the treatment 
of choice [7]. Though, to optimally treat early stage EAC 
with positive margins after endoscopic resection, additive 
treatment approaches are needed. A possible ablative 
approach is photodynamic therapy (PDT). PDT is able 
to generate cell death via non-ionizing light energy that 
interacts with photosensitizers, leading to chemical 
destruction of cells. Previous research has focused on 
implementing PDT as an alternative treatment option for 
early stage EAC and dysplastic Barrett Esophagus (BE) 
[8]. Although PDT ablation has shown to decrease the 
development of EAC, considerable side effects such as 
photo cutaneous reactions and esophageal strictures have 
also been described [9–11]. Therefore, to date, PDT is 
considered an effective salvage treatment option for patients 
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who are not fit for surgery, rather than as a first choice of 
treatment in early EAC or dysplastic BE in general [12]. 
To create a more cancer-selective PDT approach, a 
new modality known as targeted photodynamic therapy 
(tPDT) has recently been developed [13]. In tPDT cancer-
targeting agents, such as monoclonal antibodies (mAbs), 
are functionalized with a photosensitizer group to form 
a phototoxic compound. The targeted photosensitizer 
accumulates in tissue where the marker is expressed, thereby 
reducing the PDT exposure of the surrounding healthy tissue 
to a minimum. In this report we are the first to evaluate 
the application of mAb-based near-infrared (NIR) tPDT in 
EAC. We make use of mAbs directed against two receptors 
of the epidermal growth factor (EGF/ErbB) family, EGFR 
(ErbB1) and HER2 (ErbB2), which have been described to 
be overexpressed in various solid cancer types, including EC 
[14–21]. Since the receptor density varies between tumor 
types as well as between different areas in the same tumor, 
effectiveness of NIR-tPDT throughout the tumor could be 
impaired. We hypothesize that when an increased amount of 
receptors is available at the cell surface, more cancer-targeted 
phototoxic compound can bind the cancer cells, subsequently 
improving the therapeutic effect of tPDT (Figure 1). Since 
tyrosine kinase inhibitors (TKIs) can activate a positive 
feedback-loop by blocking downstream signaling, they can 
generate overexpression of the EGF-receptors on the surface 
of the cell [16, 22–24]. This report evaluates the therapeutic 
effect of cetuximab (anti-EGFR) and trastuzumab (anti-
HER2) targeted NIR-tPDT in Esophageal adenocarcinoma 
in vitro and, as a first, describes modulation of the EGFR and 
HER2 receptors with use of TKIs, as a tool to enhance the 
therapeutic effect and applicability of NIR-tPDT. 
RESULTS
EGFR and HER2 receptor modulation
Characterization of FLO-1 / OE33: baseline expression 
of EGFR and HER2 receptors
Figure 2A depicts the baseline EGFR and HER2 receptor 
baseline expression results for the two EAC cell lines and the 
growth receptor control cell lines (SW1573 and MCF-7). 
Both EAC cell lines express EGFR and HER2 (Absolute 
mean MFI values: OE33 EGFR = 135,814 / HER2 = 188,608; 
FL0–1 EGFR = 65,854 / HER2 = 26,528). The relative MFI 
values show that the OE33 cells have high expression of 
both the EGFR and HER2 receptor. In contrast, the FLO-1 
cells show a moderate EGFR and low to negative HER2 
expression; when set against the OE33 cells (100%), the FLO-1 
cells show 50% EGFR and only 14% HER2 expression.
TKI treatment for 72 hours induces significant 
up-regulation of receptor expression
From the different time points tested, 72 hours of 
lapatinib or erlotinib pretreatment was found to be the 
most effective for receptor upregulation (Supplementary 
Figure 1). In the FLO-1 cells, 72 hours of erlotinib 
pretreatment induced a significant dose-dependent 
upregulation of EGFR (max. +104%, P < 0.001; 
Figure 2B). The effect of 72 hours of lapatinib pretreatment 
on the EGFR and HER2 receptors varied greatly between 
the experiments; overall, a slight increase in receptor 
expression was seen, but due to the wide variation in 
results this difference was not significant (EGFR +15%, 
P < 0.5830 and HER2 +15%, P < 0.0616). In the OE33 
cells 72 hours of erlotinib induced a significant down-
regulation of EGFR expression (−43%, P < 0.0024; 
Figure 2C). In contrast, 72 hours of lapatinib induced a 
significant upregulation of both EGFR and HER2 receptor 
expression (EGFR +31%, P < 0.004 and HER2 +77%, 
P < 0.0046). 
We observed that pretreatment with 10 μM lapatinib 
induced apoptotic cell death (+10–30%) in both the OE33 
and the FLO-1 cell lines (Figure 3). Pretreatment with 
10 μM erlotinib induced only negligible additional cell 
kill (+10%). Finally, treatment with TKI for the duration 
of 72 hours also showed an observable growth inhibition 
as a treatment side effect in both EAC cell lines.
Targeted photodynamic therapy (tPDT) using 
near-infrared (NIR) light 
Control experiments, blocking assay and baseline 
NIR-tPDT results
Our control experiments show that both components, 
NIR irradiation and the phototoxic compound, are 
necessary to accomplish treatment effects (Supplementary 
Figure 2A). In addition, adding 133nM unbound 
IRDye700DX, which is equivalent to the dye present 
in a conjugate dose of 10 µg/ml, showed only a minor 
nonsignificant increase in cytotoxicity upon irradiation 
compared to the untreated cells (+2%, P = 0.350; 
Supplementary Figure 2B). NIR-tPDT treatment with 10 
µg/ml cetuximab-IRDye700DX resulted in significant 
more cytotoxicity compared to 133nM of unbound 
IRDye700DX (+2% vs. +54%, P = 0.017). Moreover, 
irradiation of cells treated with 10 µg/ml cetuximab-
IRDye700DX (no wash; +54%) did not result in additional 
cell death in comparison to samples where the conjugate 
was washed away after incubation (+54%). Furthermore, to 
prove specificity of targeted cytotoxic conjugate, blocking 
assays were performed (Supplementary Figure 2C). 
We observed that after blocking of the EGFR binding 
sites with an excess of 1000 µg/ml cold cetuximab, 
only an insignificant amount of cell death occurred 
(+6%, P = 0.017), comparable to untreated cells. 
The results of the baseline NIR-tPDT experiments 
in both EAC cell lines are presented in Supplementary 
Figure 3A; when applying cetuximab-IRDye700DX, we 
observed a stronger therapeutic effect in the OE33 cell 
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line compared to FLO-1 cells (+20%). Trastuzumab- 
IRDye700DX was shown to be the most effective 
conjugate in the OE33 cells, since a plateau in cell death 
(±80%) was reached already at 20 J/cm2 compared to 
40 J/cm2 for cetuximab-IRDye700DX. For both cell 
lines the percentages of cell death did not significantly 
differ between the three conjugate dosages tested 
(1 μg/μl, 5 μg/μl and 10 μg/μl of cetuximab-IRDye700DX 
or trastuzumab-IRDye700DX). The microscopic images 
presented in Supplementary Figure 3B demonstrate the 
effect of NIR-tPDT in the EAC cell lines; already after 
one hour following NIR-tPDT, both cell lines appeared 
to have a uniform orange/red colored nucleus, indicating 
rapid necrotic cell death.
Receptor modulation significantly increases the 
effect of NIR-tPDT
In the FLO-1 cell line NIR-tPDT after erlotinib 
pretreatment resulted in significant additional cell death 
(+25%) (40 J/cm2 P = 0.001; 30 J/cm2 P = 0.044; 
Figure 4). We observed that the amount of cell death did not 
differ significantly between the varying NIR light dosages 
used (30–40 J/cm2). In the OE33 cells, NIR-tPDT after 
lapatinib pretreatment resulted in significant additional 
cell death when performing cetuximab-IRDye700DX 
(+50%) and trastuzumab–IRDye700DX (+45%) mediated 
NIR-tPDT treatment (Figure 4A trastuzumab 10 J/cm2 
P = 0.001, 5 J/cm2 P = 0.002; cetuximab 20 J/cm2 
P = 0.001, 10 J/cm2 P = 0.001). It should be noted that 
pretreatment of the OE33 cells with lapatinib already 
induced apoptotic cell kill (+10–30%). To still be able to 
evaluate the effect of NIR-tPDT, we corrected our results 
for this lapatinib-induced (‘background’) cell kill. After 
doing so, receptor modulation still resulted in significant 
additional cell death when treated subsequently with NIR-
tPDT (trastuzumab: 5 J/cm2 +24% P = 0.032, 10 J/cm2 
+24% P = 0.013; cetuximab: 10 J/cm2 36% P = 0.012, 
20 J/cm2 39% P = 0.026; Figure 4B). 
DISCUSSION
This in vitro study demonstrates the potential 
application of NIR-tPDT as treatment strategy in EAC. 
We furthermore show, as a first, that pretreatment of EAC 
cells with TKI -erlotinib or lapatinib- increases EGFR 
and/or HER2 receptor expression at the cell surface. By 
modulating the receptor status of EAC cells, we were 
able to enhance the treatment effects of EGFR/HER2-
targeted NIR-tPDT. As such, we can conclude that NIR-
Figure 1: Schematic overview of NIR-tPDT treatment. Following TKI pretreatment the receptor status of the EAC cells is 
modulated. Hypothetically, more receptors will be expressed per cell and more cells will express the receptor at their cell surface as a 
result of the TKI-induced positive feedback loop. Since more phototoxic conjugate is able to bind to the target cells after modulation, the 
therapeutic effect of NIR-tPDT will be enhanced. EAC, esophageal adenocarcinoma; NIR-tPDT, near-infrared targeted photodynamic 
therapy; TKI, tyrosine kinase inhibitor; EGF, epidermal growth factor.
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tPDT seems a promising treatment option for esophageal 
adenocarcinoma and that TKI pretreatment is able to 
optimize the therapeutic effect of this novel cancer-
selective treatment, making it interesting for future clinical 
translation. 
In previous literature, some groups refer to NIR-tPDT 
as “near-infrared photo immunotherapy” (NIR-PIT); 
except for the terminology, the techniques are completely 
similar since both are IRDye700DX-based targeted PDT 
approaches. Over the last few years, the application of 
NIR-tPDT has been explored as a treatment option in 
several solid tumors; initially EGFR-targeting NIR-tPDT 
in vitro and in vivo experiments were performed using only 
the high EGFR-expressing epidermoid carcinoma cell line 
A431 [13, 25–31]. To date its use has been investigated 
in several other tumor types including glioblastoma, [32] 
ovarian cancer [33], HER2 negative and CD44-positive 
triple negative breast cancer [34–36], and head and neck 
Figure 2: EGFR and HER2 receptor expression results. (A) Absolute and relative baseline receptor results for the EAC 
(FLO-1/OE33) and control cell lines (sw1573 and MCF-7), illustrating that the OE33 are high EGFR (blue) and high HER2 (red), and 
FLO-1 intermediate EGFR and low to negative HER2 expressing cells. (B) For FLO-1 pretreatment with erlotinib resulted in significant 
upregulation of EGFR expression (+104%, 10 µM); EGFR expression significantly decreased in the OE33 cells (−43%, dashed line). 
(C) For OE33 lapatinib pretreatment resulted in significant upregulation of both EGFR (+33%) and HER2 (+77%; 10 µM). For FLO-1 
no evident upregulation of HER2 was observed. TKI, tyrosine kinase inhibitor. Results are presented using the mean (SD); *P < 0.05; 
**P < 0.001.
Oncotarget29850www.impactjournals.com/oncotarget
cancer [37]. Besides, the first-in-human phase I tPDT 
trial in patients with inoperable head and neck cancer is 
currently recruiting patients (https://clinicaltrials.gov/
ct2/show/NCT0242979). For the gastrointestinal tract, 
preclinical studies with gastric [38,39] and pancreatic 
cancer [40–42] have shown promising therapeutic 
responses to HER2 targeting NIR-tPDT treatment 
regimes. As such, we envision NIR-tPDT to be an effective 
approach in EAC as well. Especially the implementation 
of NIR-tPDT as previously described for pancreatic and 
head and neck cancer, where NIR-tPDT is applied to treat 
residual disease after surgical resection, could be a future 
application in EAC. For instance, NIR-tPDT following an 
irradical (incomplete) endoscopic mucosal resection might 
help to prevent highly invasive esophagectomy. 
Our results demonstrate that NIR-tPDT is indeed 
an effective treatment strategy in EAC in vitro. The 
NIR-tPDT experiments performed in this study target two 
receptors of the EGF family, namely EGFR and HER2. 
The receptor expression results show that OE33 is a 
high expressing EGFR and HER2 cell line, which is in 
concordance with previous literature [43]. We observed 
that FLO-1 is a cell line with average expression of EGFR 
and low to negative expression of HER2; for the FLO-1 
cells no results on receptor status have been reported thus 
far. During our baseline dose-escalation experiments, we 
concluded that the efficacy of NIR-tPDT was dependent 
mostly on the amount of NIR light exposure, and to a 
lesser extent on the conjugate dose used. This observation 
is in concordance with the results of Mitsunaga et al., who 
also concluded that the percentage of cell death in EGFR 
positive A431 cells was NIR light intensity dependent, and 
that repeated exposures of NIR light resulted in complete 
tumor responses [26]. 
Figure 3: TKI induced cell death. (A) Pretreatment with lapatinib (10 μM, 72 hr) induced apoptotic cell death (+10−30%) in both the 
FLO-1 and the OE33 cell lines. Pretreatment with erlotinib (10 μM, 72 hr) induced only negligible additional cell kill (+10%). (B) Using 
an AO/EB staining we demonstrate that TKIs induce apoptotic cell death; viable cells with intact membranes will have a uniform green 
color in their nuclei (upper row), early apoptotic cells show bright green patches in the nuclei (lower left) and late apoptotic cells have 
bright orange/red areas (lower right). Necrotic cells would have been uniform orange/red. AO/EB, acridine orange/ ethidium bromide. 
[* McGahon AJ, Martin SJ, Bissonnette RP, et al. The end of the (cell) line: Methods for the study of apoptosis in vitro. Methods Cell Biol. 
1995;46:153–185].
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NIR-tPDT is thought to be a cancer-selective 
therapy with minimal damage to surrounding healthy 
tissue [25,44]. Our study confirms this selectivity via 
a blocking assay, which resulted in a decrease of cell 
death after blocking of the EGFR binding sites with an 
excess of cold cetuximab. Furthermore, no significant 
cytotoxicity was observed in cells treated with only one 
of the components: NIR light or phototoxic conjugate. 
Previously, it was already demonstrated that EGFR 
targeted NIR-tPDT was only successful in EGFR positive 
cells by using a mixed tumor model that contained both 
receptor positive and negative cells [13,27]. Our results 
meet this assumption, since NIR-tPDT showed a higher 
cell kill in the OE33 cells compared to FLO-1; the baseline 
EGFR and HER2 receptor expression of the OE33 cells is 
considerably higher than that of the FLO-1 cells, implying 
its receptor selectivity. In addition, these results also imply 
that when more receptors are available at the cell surface, 
thus more binding sites for the phototoxic conjugate, 
this leads to more effective NIR-tPDT treatment. Our 
previous observation, that varying the NIR light intensity 
seems more effective than raising the conjugate dose 
Figure 4: NIR-tPDT following EGFR/HER2 receptor modulation. (A) In the FLO-1 cells, cetuximab-IRDye700DX NIR-tPDT 
following erlotinib pretreatment -EGFR upregulation- resulted in an additional 25% rapid, necrotic cell death. (B) In the OE33, lapatinib 
pretreatment (EGFR and HER2 upregulation) resulted in an increased therapeutic effect of both cetuximab-IRDye700DX (+50%) and 
trastuzumab-IRDye700DX (+45%) targeted NIR-tPDT. After correcting these results for the lapatinib induced cell kill (blue bar), the 
results remained significant (+24% additional cell kill). NIR-tPDT, near-infrared targeted photodynamic therapy; Results are presented 
using the mean (SD); *P < 0.005, **P < 0.0001. 
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to accomplish cell kill, might also be explained by the 
EGFR and HER2 receptor status; the amount of conjugate 
applied might already saturate all the available EGFR or 
HER2 receptors. As such, these results substantiate the 
hypothesis that receptor modulation could be a promising 
strategy for optimizing NIR-tPDT. 
Previously, Shimoyama et al. explored viral 
transduction of the extracellular domain of an 
overexpressing growth factor receptor [35]. They 
employed virus mediated HER2 transduction in negative 
HER2 expressing breast cancer cells, with which 
they concluded that NIR-tPDT resulted in effectively 
and selectively killing of the HER2-transducted cells 
in vitro. However, viral transduction is not easily clinically 
translatable, whereas receptor modulation using clinically 
applicable TKI is. Based on these observations, we 
investigated the hypothesis that upregulation of the EGF 
receptors might enhance the treatment effect of NIR-
tPDT. For the EAC cell lines used in our study, OE33 
and FLO-1, no previous literature on TKI responsiveness 
was yet available; as such, we are the first to demonstrate 
that TKI administration is indeed able to significantly 
upregulate EGFR and HER2 receptor expression in EAC 
cells. More importantly, our results demonstrate that EAC 
cells, which already express the receptor to some extent, 
will gain additive effect from NIR-tPDT treatment after 
receptor modulation. Previous literature has demonstrated 
a positive effect of TKI pretreatment in conventional 
PDT [45–47], most likely caused by augmentation of the 
vascular effects of PDT and by improving photosensitizer 
uptake. Our study is the first to show the benefit of TKI-
induced upregulation of target receptors and its positive 
effect on the NIR-tPDT treatment outcome. 
 In conclusion, this in vitro study demonstrates 
that EGFR or HER2 based NIR-tPDT is a promising 
treatment strategy in EAC. In addition, we demonstrated 
that pretreatment with the TKIs erlotinib and lapatinib 
induces significant growth receptor upregulation. This 
receptor upregulation resulted in an increased treatment 
response, making receptor modulation a promising strategy 
to optimize NIR-tPDT. Future in vivo experiments are 
required to evaluate whether clinical translation of NIR-
tPDT combined with TKI pre-treatment is indeed feasible. 
MATERIALS AND METHODS
Cell Culture
For our experiments we used four cell lines: OE33 
(obtained from Dr. Bremer, dept. of Surgical Oncology, 
UMCG, Groningen, The Netherlands), FLO-1 (obtained 
from D. Beer, dept. of Surgery, university of Michigan, 
MI, USA), SW1573 and MCF-7 (both obtained from 
ATCC, LGC Standards, Middlesex, UK); all cell lines 
were tested and authenticated by BaseClear (BaseClear 
B.V., Leiden, The Netherlands). 
The OE33 and FLO-1 are both human esophageal 
adenocarcinoma (EAC) cell lines. As positive growth 
receptor control cell lines we used SW1573, which is a 
low-expressing human non-small cell lung carcinoma cell 
line and MCF-7, which is an average EGFR-expressing 
human breast carcinoma cell line. The cells of the FLO-
1 cell line were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM); the other cell lines were cultured in 
Roswell Park Memorial Institute Medium (RPMI). All 
media were supplemented with 10% fetal calf serum 
(FCS), the medium of the SW1573 cell line also required 
glutamine (0.1%). Cells were cultured at 37 °C, in a 
humidified atmosphere containing 5% CO2. Cells were 
passaged twice a week using trypsin (0.1%); both EAC 
cell lines were passaged at 1:6, MCF-7 at 1:10 and 
SW1573 1:20.
Characterization of FLO-1 / OE33: baseline 
receptor expression analysis
To evaluate and quantify EGFR and HER2 
expression levels at baseline, receptor expression analyses 
were performed using fluorescence-activated cell sorting 
(FACS; BD Accuri C6). Per experiment, approximately 
400,000 cells were incubated with 0.625 µg of cetuximab 
(20 µg/ml; anti-EGFR) or trastuzumab (20 µg/ml; anti-
HER2), for 1 hour at 4°C while on a shaker. Afterwards 
the cells were washed twice with PBS (1 ml, 2% FCS) 
and incubated with 1.1 µg of a secondary IgG anti-
human monoclonal antibody labeled with fluorescein 
isothiocyanate (44 µg/ml; IgG-FITC, Sigma Aldrich). 
Incubation and washing of the secondary antibody was 
performed as described for the primary antibody. The 
relative mean fluorescence intensity (MFI) corrected for 
the background fluorescence signal (secondary antibody 
only), which was determined by using only the secondary 
antibody, was used as a measure of cell-surface receptor 
expression. 
To quantify the receptor expression, we made use of 
the relative mean fluorescence intensity (MFI) measured 
with FACS analyses; to accomplish a reliable comparison 
between the different experiments and cell lines, the MFI 
of the OE33 cells was set at 100%, serving as a relative 
reference.
EGFR and HER2 receptor modulation
Receptor expression analysis following TKI treatment
To achieve receptor modulation, the cells were 
incubated in culture flasks with several concentrations 
[range: 1–10 µM] of erlotinib (anti-EGFR; stock solution 
10 mM; LC Laboratories) or lapatinib (anti-EGFR and 
anti-HER2; stock solution 10 mM; LC Laboratories). After 
24, 48 and 72 hours of TKI treatment, cells were harvested 
for FACS analysis. Since non-vital cells will detach, the 
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medium of the treated cells was removed from the culture 
flasks but kept in a tube to prevent cell loss; attached cells 
were harvested using 0.5 ml trypsin per flask for 2–5 min. 
The cells were transferred into the tube with the already 
removed medium, spun (5 min, 1000 RPM, 4°C) and 
washed. Finally, the cells were resuspended in PBS (+2% 
FCS) and divided into tubes, each containing 200 µl. 
The FACS analysis performed after 72 hours of 
treatment was combined with a cell death analysis. For 
this analysis, the cells were incubated with propidium 
iodide (PI), a marker for late apoptosis and necrosis; 1 µl 
PI was added per sample, incubated for 10–15 min on ice 
and FACS analysis was performed as described for the 
baseline expression. To quantify the amount of cell death 
during FACS analysis, gates were manually drawn around 
vital (P1) and dead (P2) cells. To calculate the percentage 
of cell death per sample, the amount of cells included in 
gate P2 was set against the total amount of cells (% cell 
death = (P2)/(P1 + P2)). 
Targeted photodynamic therapy (tPDT) using 
near-infrared (NIR) light
Targeted phototoxic conjugates: cetuximab-
IRDye700DX and trastuzumab-IRDye700DX
For the synthesis of the NIR-tPDT conjugates, 
cetuximab (Erbitux®, Merck B.V. Netherlands) and 
trastuzumab (Herceptin®, Roche) were used. Antibody 
samples were taken from the daily surplus of drugs 
used for clinical application by the hospital pharmacy 
(Department of clinical Pharmacy and Pharmacology of 
the UMCG). The buffers of cetuximab and trastuzumab 
were exchanged using a PD10 desalting column 
(GE Healthcare, Dublin, IRL), in order to remove 
histidine from the solution. For this step, we used a 
phosphate-based labeling buffer at pH 8.5 to provide 
optimal conjugation conditions after buffer exchange. 
The monoclonal antibodies were incubated with 
IRDye700DX NHS ester (LI-COR Biosciences, Lincoln, 
Ne, USA): 454.4 µg IRDye700DX (64.9 µl, 7 mg/ml, 
molar ratio 4:1) was added to 8.5 mg cetuximab (2.5 ml, 
3.39 mg/ml) and 537.6 µg IRDye700DX (76.8 µl, 
7 mg/ml molar ratio 4:1) was added to 10 mg trastuzumab 
(1.75 ml, 5.6 mg/ml). Dye-antibody mixtures were 
incubated at room temperature, shielded from light, for 
120 minutes. The conjugates were analyzed for their 
concentration, purity, yield and labeling efficiency 
by use of size exclusion high performance liquid 
chromatography (SE-HPLC), which showed a label 
efficacy of 63% for cetuximab-IRDye700DX (average 
dye to protein ration 2.52:1) and 88% for trastuzumab-
IRDye700DX (average dye to protein ration 3.51:1). The 
conjugates were purified with the PD-10 column, diluted 
to a stock-concentration of 1 mg/ml using 0.9% sodium 
chloride, and stored in the dark at 4°C. 
NIR-tPDT device
A previously described, an especially designed 
light emitting diode (LED) device (Phillips Consumer 
Lifestyle B.V., Eindhoven, NLD) was used to perform 
the NIR-tPDT experiments.[37,48] The device emits 
light at a peak wavelength of 690 nm, which is suitable 
for IRDye700DX excitation. In total, 126 individual 
LEDs emit NIR light, with an adjustable light intensity 
ranging from 41–206 mW/cm2. The energy of the NIR 
light source was calculated using the formula: energy 
of the NIR light (mJ/cm2) = Intensity (mW/cm2) x Time 
(seconds). The required amount of NIR light energy was 
obtained by adjusting the light intensity (1–2.5 ampere; 
max. fluence rate 103 mW/cm2) and exposure time. Well 
plates were placed at a fixed distance of 20 cm from the 
light source. 
Control treatments and blockings assay
Control experiments were performed using cold 
cetuximab (10 µg/ml and 1000 µg/ml) and an equivalent 
of unbound IRDye700DX (133 nM) followed by NIR 
light irradiation with 0 J/cm2 and 2 J/cm2. Cells incubated 
with 10 µg/ml cetuximab-IRDye700DX and 1000 µg/ml 
cold cetuximab for 1 hour were used for blocking assay 
analysis, followed by NIR light irradiation with 0 J/cm2 
and 2 J/cm2. 
NIR-tPDT experiments: baseline dose-escalation 
and after receptor modulation
The dose escalation was performed to determine 
the optimal NIR light and conjugate dose. Cells were 
seeded in 12-well plates (1 ml of standard medium 
per well) and grown for 24 hours. The medium of the 
wells was aspirated and the conjugate diluted in RPMI 
or DMEM was added. The cells were incubated for 
1 hour at 37 °C and the conjugate was removed. The 
wells were washed twice with PBS containing 2% FCS. 
Subsequently, the plates were irradiated using the LED 
device, performed in a dark room. The total light dose 
varied from 0 J/cm2 to 60 J/cm2; max. fluence rate: 
103 mW/cm2). In addition, different dosages of conjugate 
(10–5-1 µg/ml) were tested at a fixed NIR energy (40 
or 60 J/cm2; Supplementary Table 1). Per experiment, 
one plate was shielded from NIR light, serving as 
the negative NIR irradiation control. Moreover, all 
plates were shielded from ambient light throughout 
the experiment. After NIR-tPDT, FACS analysis was 
performed to evaluate cell death.
Similar NIR-tPDT experiments were performed 
following EGF-receptor modulation. After seeding the 
cells and 24 hours of cell growth, one of the two TKIs 
was added to the 1 ml medium volume of the 12-well 
plates and incubated at 37°C for 72 hours. Thereafter the 
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NIR-tPDT protocol, as described above, was executed for the 
pretreated cells using various NIR light amounts (Table 1). 
Comprehensive cell death analysis: acridine 
orange/ ethidium bromide staining (AO/EB)
To more extensively analyze the type of cell death 
that occurs following TKI treatment and NIR-tPDT, an 
additional and more comprehensive cell death analysis was 
performed: the acridine orange/ ethidium bromide (AO/
EB) cell death analysis. Acridine orange (AO) intercalates 
into DNA and is a marker for early apoptosis. Ethidium 
bromide (EB) is only taken up by non-viable cells and is a 
marker for late apoptosis and necrosis. To analyze the type 
of cell death due to TKI treatment, the cells were cultured 
in a 96-well plate with increasing concentrations of 
lapatinib and erlotinib in 200 µl of culture medium. After 
24 and 48 hours of incubation, 1 µl of AO (0.5 mg/ml; 
Sigma) and 1 µl of EB (1 mg/ml; Invitrogen, Paisley) were 
added to the wells. After 10 min of incubation, the cells 
were spun (5 min, 1000 RPM, 21°C) and supernatants 
were discarded. For the NIR-tPDT treated cells the same 
amounts of AO/EB was added, but then within one hour 
after the tPDT treatment was finalized. Finally, the cells 
were viewed under the microscope and the percentage of 
apoptotic or necrotic cells was calculated. 
Statistical analyses
All presented results are derived from at least three 
independent experiments. The data is analyzed with 
SPSS version 23.0 and Graphpad Prism version 5.04 and 
presented as the mean and standard deviation (SD). The 
differences between the various treatment groups within 
the receptor modulation experiments was analyzed using 
a Kruskal Wallis test with a post-hoc Holms-Bonferroni 
correction for multiple testing. The effects of additional 
cell death after receptor modulated NIR-tPDT was 
analyzed using an independent, two-sided, T-test. The 
global significance level was set at P < 0.05.
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